Abstract
Abstract
Summary
Health records of patients hospitalized for osteoporotic fracture were analyzed. Prior to the index hospital admission, most patients were not receiving any antiosteoporotic treatment. During the index hospitalization visit, 25.5% of patients received antiosteoporotic treatment. The most common treatment regimens were active vitamin D3, bisphosphonates, and teriparatide.
Purpose
To examine the real-world treatment patterns and factors associated with receipt of treatment among Japanese patients with osteoporotic fracture.
Methods
We retrospectively analyzed health records of patients who were hospitalized for osteoporotic fracture between February 2016 and February 2018 in Japan. The type and duration of treatment with antiosteoporotic medications prescribed during hospital stays and after discharge were examined using descriptive statistics. Demographic and clinical factors (e.g., age, previous diagnoses, Charlson Comorbidity Index scores) associated with osteoporotic treatment were explored using multivariable logistic regression.
Results
A total of 112,275 patient medical records were evaluated, including 56,574 records from patients with hip fracture, 26,681 records from patients with vertebrae fracture, and 29,020 patients with non-vertebral non-hip fractures. Prior to the index hospital admission, most patients (91.7%, n = 102,919) were not receiving any antiosteoporotic treatment. For those receiving treatment, active vitamin D3 (51.1%, n = 4778) and bisphosphonates (47.5%, n = 4441) were the most common. During the index hospitalization visit, 25.5% (n = 28,678) of patients received treatment for their fracture, including active vitamin D3 (n = 17,074), bisphosphonates (n = 10,007), and teriparatide (n = 4561). Upon discharge, 41.5% (n = 46,536) of patients returned to their home and 34.3% (n = 38,542) of patients were transferred to a different hospital or medical care facility. Variables associated with receipt of treatment at follow-up included older age, previous diagnoses of osteoporosis and fracture, and higher Charlson Comorbidity Index scores.
Conclusion
Despite osteoporotic fracture being a major health concern within older Japanese populations, treatment with antiosteoporotic medication regimens remains generally low.
Publisher
Springer Science and Business Media LLC
Subject
Orthopedics and Sports Medicine
Reference30 articles.
1. Iki M (2012) [Epidemiology of osteoporosis in Japan]. Clin Calcium 22(6):797–803. http://dx.doi.org/CliCa1206797803
2. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18(8):1547–1553. https://doi.org/10.1359/jbmr.2003.18.8.1547
3. Hagino H (2021) Current and future burden of hip and vertebral fractures in Asia. Yonago Acta Med 64(2):147–54. https://doi.org/10.33160/yam.2021.05.001
4. Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20(5):695–702. https://doi.org/10.1007/s00198-008-0761-5
5. Hosoi T (2015) [On “2015 Guidelines for prevention and treatment of osteoporosis.” Diagnostic criteria of primary osteoporosis and the criteria for pharmacological treatment]. Clin Calcium 25(9):1279–83. http://dx.doi.org/CliCa150912791283
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献